HOOK (HOOKIPA Pharma) Other Operating Expense: $-3.04 Mil (TTM As of Jun. 2025)


HOOK HOOKIPA Pharma Inc HOOK
50 GF Score
Price $1.15
View Full Analysis

What is HOOKIPA Pharma Other Operating Expense?

HOOKIPA Pharma HOOK 50 Other Operating Expense is $-3.04 Mil as of Jun. 2025. GuruFocus rates HOOK with a GF Score™ of 50/100.

HOOKIPA Pharma's Other Operating Expense for the three months ended in Jun. 2025 was $-0.16 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2025 was $-3.04 Mil.

HOOKIPA Pharma's quarterly Other Operating Expense increased from Dec. 2024 ($-0.47 Mil) to Mar. 2025 ($-0.23 Mil) and increased from Mar. 2025 ($-0.23 Mil) to Jun. 2025 ($-0.16 Mil).

HOOKIPA Pharma's annual Other Operating Expense declined from Dec. 2022 ($-7.92 Mil) to Dec. 2023 ($-11.19 Mil) but then increased from Dec. 2023 ($-11.19 Mil) to Dec. 2024 ($-7.40 Mil).

HOOKIPA Pharma Other Operating Expense Historical Data

* Premium members only.

The historical data trend for HOOKIPA Pharma's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HOOKIPA Pharma Other Operating Expense Chart

HOOKIPA Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Operating Expense
Get a 7-Day Free Trial -6.52 -9.72 -7.92 -11.19 -7.40

HOOKIPA Pharma Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.51 -2.18 -0.47 -0.23 -0.16
HOOK
50GF Score
HOOKIPA Pharma Inc HOOK
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HOOKIPA Pharma Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of $-3.04 Mil mean?
HOOKIPA Pharma (HOOK) has a Other Operating Expense of $-3.04 Mil as of Jun. 2025. Other operating expenses that a company records on its income statement. View historical data on HOOKIPA Pharma and its competitors.
Is HOOKIPA Pharma's Other Operating Expense too high?
HOOKIPA Pharma's current Other Operating Expense is $-3.04 Mil. Overall, HOOKIPA Pharma has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does HOOKIPA Pharma's Other Operating Expense compare to COCP and LNAI?
HOOKIPA Pharma's Other Operating Expense of $-3.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on HOOKIPA Pharma and its competitors. HOOKIPA Pharma's current Other Operating Expense is $-3.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HOOKIPA Pharma stock overvalued right now?
HOOKIPA Pharma (HOOK) has a current Other Operating Expense of $-3.04 Mil. The current Other Operating Expense is $-3.04 Mil. HOOKIPA Pharma's overall GF Score™ is 50/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For HOOKIPA Pharma (HOOK), the current Other Operating Expense is $-3.04 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HOOKIPA Pharma Business Description

Address 350 Fifth Avenue, 72nd Floor, Suite 7240, New York, NY, USA, 10118
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company's product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. In addition, It is also focused to develop therapies that are intended to provide functional cures for hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1).
50GF Score

Get the complete analysis for HOOK

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.15
Price